- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01405885
A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus
Phase I, Open Label Study to Evaluate Safety, Tolerability and Immunogenicity of Multiple Combinations of H1 and H5 Influenza Hemagglutinin Plasmids Administered ID Followed by in Vivo Electroporation With CELLECTRA®-3P in Healthy Adults
Study Overview
Status
Conditions
Detailed Description
The use of DNA plasmids containing genes that express viral antigens may be a promising way to formulate a vaccine that can effectively prevent infection and disease caused by the H5N1 avian influenza virus and H1N1 influenza viruses. Plasmid vectors are simple to construct and are easy to manufacture at a relatively low cost. Vaccination with plasmids that express influenza proteins should induce the development of serum antibodies and might also induce significant quantities of secretory IgA antibodies and/or CMI. The DNA sequences included in the vaccine could also result in the proliferation of T lymphocytes that could broaden the effectiveness of the vaccine to include variant strains of H5N1 and H1N1 with antigenically modified HA (i.e., drifted strains).
Electroporation (EP) is a technology in which a transmembrane electrical field is applied to increase the permeability of cell membranes to create microscopic pathways (pores) and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. Their presence allows macromolecules, ions, and water to pass from one side of the membrane to the other. The presence of a constant field influences the kinetics of directional translocation of the macromolecular plasmid, such that the plasmid delivery in vivo has been sufficient to achieve physiological levels of secreted proteins. ID injection of a plasmid followed by EP has been used very successfully to deliver therapeutic genes that encode for a variety of hormones, cytokines, or enzymes in a variety of species. EP is currently being used in humans to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.
The use of EP via the CELLECTRA® device should increase the expression of H5N1 and H1N1 influenza virus genes in the study vaccines.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33143
- Miami Research Associates
-
-
Kansas
-
Overland Park, Kansas, United States, 66212
- Vince and Associates
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- SNBL
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent in accordance with institutional guidelines. If required by local law, candidates must also authorize the release and use of protected health information (PHI);
- Adults of either gender 18-55 years of age at entry;
- Healthy subjects as judged by the Investigator based on medical history, physical examination, and normal results for an ECG, CBC, serum chemistries, and urinalysis done up to 4 weeks prior to enrollment and administration of vaccination ± EP;
- Current nonsmoker;
- Women of child-bearing potential (WOCBP) agree to remain sexually abstinent, use medically effective contraception (oral contraception, barrier methods, spermicide, etc), or have a partner who is sterile (i.e., vasectomy) until 12 weeks after last vaccination;
- Able and willing to comply with all study procedures.
Exclusion Criteria:
- Positive serological test for Human Immunodeficiency Virus, hepatitis C virus or hepatitis B virus surface antigen (HBsAg) or Grade 3 or greater CPK at screening;
- Pregnant or breastfeeding subjects;
- Any concurrent condition requiring the continued use of systemic or topical steroids at or near the injection site (excluding inhaled and eye drop-containing corticosteroids) or the use of other immunosuppressive agents. All other corticosteroids must be discontinued > 4 weeks prior to Day 0 of study vaccine administration;
- Administration of any blood product within 3 months of enrollment;
- Prior receipt of any investigational or licensed H5N1 influenza vaccine at any time;
- Subjects with contraindications to influenza vaccination other than egg allergy (such as a history of Guillain-Barre Syndrome after receiving influenza vaccine);
- Administration of any vaccine within 6 weeks of enrollment;
- Participation in a study with an investigational compound or device within 4 weeks of signing informed consent;
- Subjects with cardiac pre-excitation syndromes (such as Wolff-Parkinson-White);
- Subjects with a history of seizures (unless seizure free for 5 years);
- Subjects with tattoos, scars, or active lesions/rashes within 2 cm of the site of vaccination ± EP;
- Subjects with any implantable leads;
- Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements;
- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (i.e. infections disease) illness must not be enrolled into this study;
- Any other conditions judged by the investigator that would limit the evaluation of a subject.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A - 0.9mg of INO-3605
|
0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
|
Experimental: Arm B - 0.9mg of INO-3609
|
0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.
0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8
1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
|
Experimental: Arm C- 0.9mg of INO-3401
|
0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
|
Experimental: Arm D- 0.3mg of INO-3609
|
0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.
0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8
1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
|
Experimental: Arm E - 0.45mg each INO-3605 , INO-3609
|
0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
|
Experimental: Arm F - 0.3mg each of INO-3401,INO-3605,INO-3609
|
0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
|
Experimental: Arm G - 0.9mg of INO-3609
|
0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.
0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8
1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
|
Experimental: Arm H - 0.9mg of INO-3609
|
0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.
0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8
1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
|
Active Comparator: Arm I - Seasonal influenza vaccine
|
0.5ml of vaccine delivered IM
|
Experimental: Arm J - 1.8mg of INO-3609
|
0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.
0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8
1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of nine different formulation of multiple combination of H1 and H5 HA plasmid administered ID followed by electroporation in healthy adult subjects
Time Frame: Day 0 through Month 12
|
Frequency and severity of local and systemic reactogenicity signs and symptoms, adverse events and serious adverse events
|
Day 0 through Month 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Humoral and cellular immune responses
Time Frame: Day 0 through Month 12
|
Magnitude and frequency of antibody and cell mediated immune response to influenza proteins
|
Day 0 through Month 12
|
tolerability and immunogenicity of multiple formulations of H1 and H5 HA plasmids administered ID followed by electroporation to seasonal influenza vaccine
Time Frame: Day 0 through Month 12
|
Day 0 through Month 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Mark Bagarazzi, M.D., Inovio Pharmaceuticals
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FLU-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on INO-3605
-
Inovio PharmaceuticalsGeneOne Life Science, Inc.; Defense Advanced Research Projects AgencyCompleted
-
Inovio PharmaceuticalsUniversity of PennsylvaniaCompletedAerodigestive Precancerous Lesions and MalignanciesUnited States
-
Inovio PharmaceuticalsUniversity of PennsylvaniaCompletedHead and Neck Squamous Cell CancerUnited States
-
Inovio PharmaceuticalsMayo Clinic; University of Pennsylvania; University of Pittsburgh; Thomas Jefferson... and other collaboratorsCompletedBreast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | ColoRectal Cancer | HepatoCellular CarcinomaUnited States
-
Moroccan Society of SurgeryInstitut National d'Oncologie Sidi Mohammed Ben AbdellahCompletedLearning OrganizationMorocco
-
Inovio PharmaceuticalsCompletedProstate CancerUnited States
-
Inovio PharmaceuticalsWithdrawnCoronavirus Infection
-
University of PennsylvaniaInovio PharmaceuticalsRecruiting
-
Inovio PharmaceuticalsCompletedCervical CancerUnited States
-
Inovio PharmaceuticalsCompletedHepatitis BAustralia, Taiwan, United States, Singapore, New Zealand, Hong Kong, Thailand, Philippines